Edaravone suspension for oral administration | Patent Number 11826352

US 11826352 B2
Application Number17308399
Publication NumberUS 20210251965 A1
Pendency2 years, 6 months, 27 days
Filled DateMay 5, 2021
Priority DateNov 1, 2019
Publication DateAug 19, 2021
Expiration DateOct 31, 2039
Inventor/ApplicantsTomoyuki Omura
Tomohiro Takahashi
Tetsuo HAYAMA
Tomoyuki OMURA
Munetomo MATSUDA
Tadashi MIYAZAWA
Kouji Hayashi
Kouji HAYASHI
Tomohiro TAKAHASHI
Tadashi Miyazawa
Munetomo Matsuda
Tetsuo Hayama
ExaminesCHANNAVAJJALA, LAKSHMI SARADA
Art Unit1611
Technology Center1600
Assignments
Mitsubishi Chemical Group Corporation
Current
Mitsubishi Chemical Group Corporation
Original
Law Firm
You must be logged in to view
Login
Attorneys
Subscription-Only
View Concierge Program
Patent Prosecution report image

Empower your practice with Patexia Publication Prosecution IP Module.

Get access to our exclusive rankings and unlock powerful data.
Check our Latest ReportPurchase IP Module

Looking for a Publication Attorney?

Get in touch with our team or create your account to start exploring a network of over 120K attorneys.